New antibody PRL3-Zumab tested against advanced cancers

NCT ID NCT07290088

Recruiting now Disease control Sponsor: Intra-IMMUSG Pte Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called PRL3-zumab in 52 adults with advanced solid tumors. The drug is given by IV every two weeks. Researchers want to see if it can slow cancer growth and how safe it is. Participants must have had no more than three prior treatments and be in relatively good health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRL3-zumab (an experimental antibody given by IV infusion every 2 weeks)
What this could lead to: If successful, this could provide a new treatment option to slow tumor growth in patients with advanced solid cancers.
What could go wrong: This is an early-to-mid-stage trial with only 52 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID CANCERS

Contacts and locations

Locations

Beacon Hospital
RECRUITING

Kuala Lumpur, Malaysia
Hosp. Kuala Lumpur
RECRUITING

Kuala Lumpur, Malaysia
Hosp. Universiti Sains Malaysia (HUSM), Kelantan
RECRUITING

Kota Bharu, Malaysia
University Malaysia Medical Centre
RECRUITING

Kuala Lumpur, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.